Plavix Label Revised To Include Prilosec Warning

By Leigh Kamping-Carder

Law360, New York (November 18, 2009, 5:16 PM ET) -- The U.S. Food and Drug Administration has announced labeling changes to Plavix, manufactured by Sanofi-Aventis SA and Bristol-Myers Squibb Co., to reflect new data showing that simultaneously taking the heartburn treatment Prilosec can sharply reduce the effects of the blockbuster blood thinner.

Taking proton pump inhibitors, a type of drug that includes Prilosec and Nexium, can block the effectiveness of the anti-clotting drug clopidogrel, co-marketed as Plavix, the FDA warned on Tuesday.

Clopidogrel, an anti-platelet that is used to prevent blood clots that could lead to...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles